GSK Consent Decree Includes $650 Mil. Bond, Third-Party Inspections
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline appears to have negotiated a more favorable consent decree agreement with FDA compared to previous pharmaceutical companies facing similar action
You may also be interested in...
GSK Consent Decree Sets “Aggressive” 150-Day Timeline For GMP Conformity
GlaxoSmithKline's consent decree mandates that the company notify the agency within 150 days of the corrective measures it has taken or plans to take in addressing FDA's good manufacturing practice concerns
FDA Seizure Of GSK Products Exemplifies Heightened Warning Letter Gravitas
The seizure of two of GlaxoSmithKline's major prescription drugs is an example of the increased seriousness FDA is placing on individual warning letters
Schering Claritin Awaits FDA Certification; Correctol SKUs To Be Discontinued
Schering-Plough's first batch of products submitted to FDA for certification under a May 16 consent decree will include the Claritin 10 mg dose